CHMP recommend market authorisation for biosimilar bevacizumab (Equidacent brand)

Studies found that this brand was highly similar to the reference product Avastin, which was authorised in the EU in 2005. Data show that Equidacent has comparable quality, safety and efficacy to Avastin. It will be licensed for the range of indications as per Avastin.


European Medicines Agency